Toni Choueiri, MD
Enriched profileDirector, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Toni Choueiri is Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 2,494 publications with 128,964 citations (h-index 152); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Toni K. Choueiri is Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. The public record shows 2,494 publications with 128,964 citations (h-index 152), centered on Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 12 registered clinical trials, 7 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · The New England journal of medicine
- Top research focus: Renal cell carcinoma treatment
- 12 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 134 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 907.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- As FDA ODAC member
voted on/commented on drug approval matters (e.g., recommended PTEN expression ≥90% cutoff for capivasertib indication due to toxicity concerns; voted on camizestrant for HR+/HER2- breast cancer)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- ABEMA Alone or in COMBO With MK-6482
Sponsor: Dana-Farber Cancer Institute
Industry payments
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202515 payments$28,489openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202512 payments$14,977openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Inlyta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
7 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Optimizing neoadjuvant/adjuvant anti-PD-1 therapy for localized Renal Cell Carcinoma
Brigham and Women'S Hospital
FY2026$740,020R01CA308071 - Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
Dana-Farber Cancer Inst
FY2026$713,011R01CA266424
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.
The New England journal of medicine
Clinical Trial2026 - Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal for immunotherapy of cancer
Clinical Trial2026 - Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.
Nature medicine
Article2026
Most-cited works
by citation count (OpenAlex)- 01The Immune Landscape of Cancer6,200 citations2018
- 02Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma5,896 citations2015
- 03Post-acute COVID-19 syndrome5,025 citations2021
- 04Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma4,647 citations2018
- 05Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma3,395 citations2017
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/toni-choueiri-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/toni-choueiri-924b9614b
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Toni-Choueiri
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
themedicinementors.libsyn.com/the-true-mark-of-success-with-dr-toni-choueiri
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themedicinementors.libsyn.com ↗ - Instagram
instagram.com/curetoday/reel/DAQqvqRvZcf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/danafarber/p/CqTBEowufVF
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Medical Director
International Strategic Initiatives, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Co-leader
Kidney Cancer Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Attending Physician
Medical Oncology, Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
- Regular video contributor/author
OncLive (multiple interviews on RCC treatment developments)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Interview
CancerNetwork - 'How New Data Impact the Standard of Care for RCC'
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Nikhil Munshi, MD
Dana-Farber Cancer Institute